SCHEDULE 13G: Seven Fleet Partners Discloses 0.2% Passive Stake in CytomX Therapeutics

Seven Fleet Partners LP, Seven Fleet Advisors LLC, and Brian Liu have jointly filed a Schedule 13G, reporting a passive beneficial ownership of 0.2% in CytomX Therapeutics, Inc.

Summary

• Seven Fleet Partners LP, Seven Fleet Advisors LLC, and Brian Liu (collectively, "Reporting Persons") have jointly filed a Schedule 13G with the SEC.
• The Reporting Persons collectively beneficially own 377,161 shares of Common Stock in CytomX Therapeutics, Inc.
• This ownership represents 0.2% of CytomX Therapeutics' total outstanding Common Stock.
• The percentage is calculated based on 157,544,369 shares of Common Stock outstanding, as reported by CytomX Therapeutics in its prospectus supplement filed on May 12, 2025.
• The filing indicates a passive investment purpose, certifying that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
• The Reporting Persons acknowledge a potential "group" relationship with Longitude Capital Management Co. LLC, which beneficially owns 11,538,461 shares (7.3%) of CytomX Therapeutics, but they expressly disclaim such group membership and beneficial ownership over Longitude's shares.

Sentiment

Score: 5

Explanation: The filing of a Schedule 13G for a passive 0.2% stake is generally neutral. It indicates an investor has taken a small position without intent to influence control, providing minimal new information regarding the company's performance or outlook.

Positives

• The filing indicates a passive investment, suggesting no immediate intent from the Reporting Persons to disrupt company operations or strategy.
• The Reporting Persons have certified that their investment is not for the purpose of changing or influencing control of the issuer.

Negatives

• The reported stake of 0.2% is very small and unlikely to provide significant influence or signal strong conviction in the company's future performance.

Risks

• The Reporting Persons acknowledge that they, along with Longitude Capital Management Co. LLC, may be deemed to be members of a "group" under Section 13(d)(3) of the Securities Exchange Act of 1934, despite expressly disclaiming such group membership.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a new, albeit minor, passive investor in the company. The small stake is unlikely to have a significant direct impact on shareholder value.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this beneficial ownership filing.

Key Dates

Keywords

CytomX Therapeutics, Seven Fleet Partners, Seven Fleet Advisors, Brian Liu, Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment, SEC Filing, Therapeutics